Scott Alexander examines the risks of Adderall use, analyzing medical, addiction, tolerance, and neurotoxicity concerns, concluding that the benefits outweigh the risks for well-informed patients. Longer summary

Scott Alexander explores the risks of Adderall use, examining medical risks, addiction potential, tolerance development, and possible neurotoxicity. He critically analyzes existing research and shares his clinical experience, ultimately concluding that while there are some concerning risks, they are not severe enough to stop prescribing stimulants to patients who might benefit from them, provided they are well-informed about the risks. Shorter summary

Scott argues against Vox's proposal for drug price controls, citing studies that such policies would significantly reduce pharmaceutical innovation and potentially cost millions of life-years long-term. Longer summary

Scott Alexander responds to Sarah Kliff's Vox article about drug pricing, arguing that her proposal for price controls on brand-name drugs would significantly decrease pharmaceutical innovation. He cites multiple economic studies suggesting price controls reduce R&D and new drug development. Scott argues that while price controls might lower costs in the short-term, they could cost millions of life-years long-term by reducing new drug creation. He suggests focusing on increasing generic drug competition and reducing unnecessary prescriptions of expensive brand-name drugs with cheap generic alternatives as better solutions to high drug prices. Shorter summary

Scott Alexander reviews a wide range of treatments for anxiety disorders, from lifestyle changes and therapy to medications and alternative remedies, emphasizing the importance of exploring multiple options. Longer summary

Scott Alexander provides an extensive overview of various treatments for anxiety disorders, covering diet and lifestyle changes, therapy options, conventional medications, and alternative treatments. He emphasizes the importance of lifestyle interventions like exercise and sleep, discusses the efficacy of cognitive-behavioral therapy and exposure therapy, and reviews various medication classes including SSRIs, SNRIs, and benzodiazepines. The post also explores alternative treatments like supplements and experimental drugs, concluding that while no single treatment stands out as extremely effective, there are many options available for those dealing with anxiety. Shorter summary

Scott Alexander analyzes online drug ratings, finding patients prefer older antidepressants while doctors prefer newer ones, and explores potential explanations for this paradox. Longer summary

Scott Alexander analyzes patient ratings of antidepressants from online databases, finding that older drugs like MAOIs are rated higher than newer ones. He then compares this to doctor ratings, discovering a negative correlation between patient and doctor preferences. The post explores possible explanations for these paradoxical results, including confounding factors and the hypothesis that newer antidepressants may actually be less effective. Scott extends the analysis to other drug classes, finding the negative doctor-patient correlation holds broadly, while the preference for older drugs is specific to psychiatric medications. Shorter summary